Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: July 13, 2006
- Previous Holding: 17,369,810 ADRs
- New Holding: 17,337,570 ADRs
- Average Price: $56.39
- Reason: A movement in the fund.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that the Plan is a discretionary fund for employees and former employees. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are potentially interested in the shares held in the fund in the same manner as other employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total reduction of 32,240 ADRs in the US Retirement Savings Plan.
- Confirm the average transaction price of $56.39 per ADR.
- Note that the change was driven by fund movements rather than direct director trading.
- Recognize that this filing does not impact the company's consolidated financial statements.